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To the Editor: As prophylaxis, trimethoprim-sulphamethoxa-
zole (co-trimoxazole) is mainly used for prevention of
Pneumocystis jiroveci (previously carinii) pneumonia (PCP) and
toxoplasmosis in AIDS patients. Co-trimoxazole may also
prevent other opportunistic infections, such as salmonellosis,
bacterial pneumonia, nocardiosis and isosporiasis. It is
inexpensive and widely available, rendering it suitable as a
general prophylactic agent against a range of opportunistic
infections.
In 2000, the joint United Nations Programme on HIV/AIDS
(UNAIDS) and the World Health Organisation (WHO)
published provisional recommendations on the use of co-
trimoxazole prophylaxis in HIV/AIDS patients, stating that it
should be used for prophylaxis in adults and children living
with HIV/AIDS in Africa as part of a minimum package of
care. It should be offered to HIV-positive adults with
symptomatic HIV disease (stages 2, 3 or 4 of the WHO
classification of HIV infection and disease), asymptomatic
individuals with a CD4 cell count ≤ 500/µl, and pregnant
women after the first trimester.1 The recommendations were
based on the findings of two randomised controlled trials on
adults in Côte d’Ivoire — the first showed that co-trimoxazole
prophylaxis significantly decreased hospitalisation and death
in patients with tuberculosis;2 the second showed reduced rates
of bacterial pneumonia, malaria, isosporiasis and acute
unexplained fever in early HIV infection.3
The South African HIV/AIDS Policy Guidelines for adults
recommend co-trimoxazole for PCP prophylaxis, and in all
symptomatic HIV-infected individuals (WHO clinical stages 2,
3 or 4) or patients with a CD4 count below 200/µl.4 Guidelines
for managing HIV infection in children recommend that any
infant born to an HIV-positive woman, symptomatic HIV-
infected children and asymptomatic HIV ELISA-positive
children receive co-trimoxazole prophylaxis from 4 - 6 weeks to
at least 15 months of age.5
Several recent studies have investigated the efficacy of
prophylactic co-trimoxazole. In Cape Town, use of prophylactic
low-dose co-trimoxazole in HIV-infected adults resulted in a
survival benefit consistent with previous trials, except in
patients who were WHO stage 2 or who had CD4 counts of 
200 - 500/µl.6 In contrast, a study in Dakar, Senegal,7 did not
show a beneficial effect of chemoprophylaxis on survival or
occurrence of opportunistic infections. In an 11-site USA study,8
co-trimoxazole prophylaxis for PCP was associated with
significantly decreased risk of toxoplasmosis, salmonellosis,
Haemophilus and staphylococcal infections but not
pneumococcal, Klebsiella and Pseudomonas infections.
Elsewhere, in Ohio, chronic prophylactic administration of co-
trimoxazole led to less frequent isolation of Staphyloccocus
aureus and enterobacteriaceae.9 However, in San Francisco, a
marked increase in co-trimoxazole resistance was observed in
HIV-infected patients, from 6.3% in 1988 to 53% in 1995,
particularly in Escherichia coli and S. aureus isolates. The
increase was greater in sterile-site isolates from HIV care units
compared with non-HIV units. Co-trimoxazole resistance was
associated with a rise in multidrug resistance. A rapid increase
in the use of co-trimoxazole for PCP prophylaxis was
implicated.10
Co-trimoxazole susceptibility was investigated
retrospectively among isolates from invasive bloodstream and
cerebrospinal fluid (CSF) infections in adults and children,
regardless of HIV status, at Chris Hani Baragwanath (CHB)
Hospital during the periods 1 October 1998 - 30 September
1999 and 1 January 2000 - 31 December 2002. The study was
confined to selected organisms commonly causing respiratory
and urinary tract infections and septicaemia in HIV-infected
patients. Blood cultures were processed using the BacT/Alert
system; CSF specimens were analysed using routine
methodology. Antimicrobial susceptibility tests were
performed using agar disk diffusion according to National
Committee for Clinical Laboratory Standards (NCCLS) criteria.
A minority of strains interpreted as intermediate were included
in the resistant category.
Results showed that co-trimoxazole resistance increased in
most invasive organisms tested during the 4-year period and
rates were usually higher in children than in adults. Tables I
and II show co-trimoxazole resistance rates in selected Gram-
positive cocci and Gram-negative bacilli respectively. Among
Streptococcus pneumoniae isolates, there was a significant
increase in resistance in adult and paediatric isolates. A
significant increase in resistance occurred in adult and total
isolates of S. aureus. Among non-typhoidal salmonellae, there
was a significant progressive increase in resistance in adult and
paediatric isolates, with consistently higher rates in children.
Resistance was initially high in E. coli strains, and remained
high throughout. H. influenzae resistance increased significantly
in adults and children. Among Klebsiella spp., the rise in
resistance varied over time, but was significant in adult and
total isolates.
Further analysis of co-trimoxazole resistance in S.
pneumoniae isolates in 2001 - 2002 showed that 24% (60/246)
versus 15% (4/27) (p = 0.265) of HIV-infected compared with
non-infected adults and 54% (81/151) v. 15% (6/39) (p < 0.001)
of children respectively, were resistant.
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Since co-trimoxazole resistance rates increased significantly
during the study period in S. pneumoniae, S. aureus, non-
typhoidal Salmonella, H. influenzae and Klebsiella spp., and
remained high among E. coli strains, co-trimoxazole
prophylaxis for opportunistic infections caused by these
bacteria may often be suboptimal or ineffective in our setting.
There were limitations to our study however. It was not
possible to separate nonsocomial from community-acquired
infections, therefore resistance levels may be lower in the
community. Except for S. pneumoniae, we did not compare
isolates from HIV-positive and HIV-negative individuals.
However, HIV-infected patients often yield isolates with higher
resistance levels than those of HIV-uninfected patients.
Currently, co-trimoxazole is frequently used in a range of
health care settings as a first-line agent, mainly in the treatment
of respiratory and urinary tract infections. We are concerned
that widespread use of co-trimoxazole may greatly increase
resistance and that the efficacy of this agent for the general
population will wane rapidly. If significant resistance develops,
co-trimoxazole may not easily be replaced by another effective,
cheap and available compound. Another concern regarding
widespread use is the occurrence of adverse reactions.
Sulphonamide therapy among children in the general
population is safe, with an overall adverse reaction rate of 5%,
but in HIV-positive children this may reach 40%, involving
neutropenia, erythema multiforme, and Stevens-Johnson
syndrome.11 In adults with AIDS treated with high-dose co-
trimoxazole for PCP in our hospital, rashes were seldom
observed, but haematological side-effects were relatively
common.12
In conclusion, the current high and increasing levels of
resistance in invasive opportunistic bacteria, important in HIV
disease, are of great concern. The WHO recommendation that
co-trimoxazole be prescribed broadly as a prophylactic agent in
HIV/AIDS-infected individuals cannot therefore be fully
endorsed. We would recommend review of guidelines and a
more restrictive approach, taking into consideration the higher
background resistance to co-trimoxazole. Guidelines should
focus on those who are likely to benefit most from prophylaxis.
When co-trimoxazole is prescribed it should be administered to
patients who are under medical care and who are followed up
regularly to monitor compliance and side-effects.
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Table I. Co-trimoxazole resistance in Gram-positive cocci
Year
1999 2000 2001 2002
Organism Patients % N % N % N % N p-value 
Steptococcus Adult 16.9 60/355 19.8 67/339 23.2 103/444 32.1 117/364 < 0.001
pneumoniae Paediatric 32.3 40/124 50.0 73/146 47.0 117/249 52.1 111/213 0.003
Total 20.9 100/479 28.9 140/485 31.7 220/693 39.5 228/577 < 0.001
Staphylococcus Adult 17.6 66/374 35.8 93/260 40.0 94/235 32.9 125/380 < 0.001
aureus Paediatric 41.5 22/53 29.0 31/107 34.0 32/94 43.4 46/106 0.298
Total 20.6 88/427 33.8 124/367 38.3 126/329 35.2 171/486 < 0.001
Table II. Co-trimoxazole resistance in Gram-negative bacilli
Year
1999 2000 2001 2002
Organism Patients % N % N % N % N p-value 
Non-typhoidal Adult 5.0 5/101 7.0 8/114 23.1 31/134 40.9 65/159 < 0.001
Salmonella Paediatric 18.4 7/38 35.3 18/51 38.9 14/36 49.1 27/55 0.009
Total 8.6 12/139 15.8 26/165 26.5 45/170 43.0 92/214 < 0.001
Escherichia Adult 66.0 165/250 75.6 170/225 76.4 191/250 72.3 204/282 < 0.120
coli Paediatric 88.6 101/114 77.4 103/133 79.2 103/130 82.2 125/152 0.348
Total 73.1 266/364 76.3 273/358 77.4 294/380 75.8 329/434 0.366
Haemophilus Adult 42.9 3/7 25.0 3/12 50.0 6/12 87.5 7/8 0.034
influenzae Paediatric 22.2 12/54 40.0 14/35 44.4 12/27 69.2 18/26 < 0.001
Total 24.6 15/61 36.2 17/47 46.2 18/39 73.5 25/34 < 0.001
Klebsiella spp. Adult 33.0 70/212 37.7 52/138 33.1 52/157 58.3 91/156 < 0.001
Paediatric 53.8 63/117 61.0 89/146 38.8 52/134 59.1 68/115 0.609
Total 40.4 133/329 49.6 141/284 35.7 104/291 58.7 159/271 0.002
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Epidemiological studies on the extent of co-trimoxazole
resistance are also necessary in various urban and rural centres
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To the Editor: In South Africa, deaths due to unnatural causes
among adults aged 15 - 49 years underwent a major decline
during the second half of the 1990s. This reduction has gone
almost unnoticed. Table I shows published data from Statistics
South Africa (Stats SA) for the period 1993 - 1996, based on all
registered deaths.  As no similar figures have been published
for the period 1997 - 2000, the closest data available are those
obtained from the Department of Home Affairs population
register and published by Stats SA (without breakdown into
natural and unnatural deaths). Since the population register
data are only for those with ID numbers it has been necessary
to adjust them to compensate for those without ID numbers to
make these data comparable to full deaths data published by
Stats SA for the earlier period. This was done by first
calculating age and sex-specific ratios for the number of
unnatural deaths in the full deaths data and the population
register data for 1996. These ratios were then applied to the
population register data for 1997 - 2000. These adjusted
numbers are unofficial and are shown in Table I in italics.
These numbers, as reflected in Figs 1 and 2 for males and
females respectively, show that while deaths due to these
causes had been rising since 1993, the turning point occurred in
1996 for males and in 1997 for females. Since then, unnatural
deaths have been on the decline for both males and females.
These preliminary findings are supported by recent data
released by Stats SA (2002)6 based on a 15.0% sample of all
registered deaths from 1997 to 2001. These data show that as a
percentage of all male deaths in the sample (N = 150 969),
Unnoticed decline in the number of unnatural deaths in
South Africa
Table I. Number of deaths among males and females aged 15 - 49
years for the period 1993 - 1996 (reported deaths) and the period
1997 - 2000 (estimated)
Males Females
Unnatural Natural Unnatural Natural 
Year deaths deaths deaths deaths
1993 24 062 19 558 5 328 13 759
1994 25 852 21 208 5 841 15 937
1995 33 706 29 158 7 512 22 366
1996 36 478 38 565 8 627 30 394
1997 36 887 45 364 8 826 37 996
1998 34 900 58 220 8 427 50 357
1999 31 999 70 504 7 879 65 394
2000 29 560 80 989 6 843 82 343
Source: Stats SA (various years)1-4 (for data from 1993 to 1996, and Stats SA (2001)5 for
the unadjusted data from 1997 to 2000. 
